{"disease":{"id":"homozygous-familial-hypercholesterolemia","name":"Homozygous Familial Hypercholesterolemia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"caduet","indication_name":"Homozygous Familial Hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."},{"drug_id":"evinacumab-dgnb","indication_name":"Homozygous familial hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"EVKEEZA","generic_name":"EVINACUMAB-DGNB","company_name":"REGENERON PHARMACEUTICALS","drug_phase":"marketed","molecular_target":"Angiopoietin-related protein 3","drug_class":"Angiopoietin-like 3 Inhibitor [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"evinacumab","indication_name":"Homozygous familial hypercholesterolemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Evkeeza","generic_name":"EVINACUMAB","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Angiopoietin-related protein 3","drug_class":"Angiopoietin-like 3 Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Evkeeza works by blocking the action of Angiopoietin-related protein 3, a protein that helps regulate cholesterol levels in the blood."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03814187","title":"Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3275,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04815005","title":"HoFH, the International Clinical Collaborators Registry","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT03234127","title":"Study of cardiovAscular Contrasted Phenotypes in Patients With FamIliaI hypercholesteRolemia","phase":"NA","overall_status":"COMPLETED","enrollment_count":562,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT02135705","title":"LOWER: Lomitapide Observational Worldwide Evaluation Registry","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Amryt Pharma","has_results":false},{"nct_id":"NCT05682378","title":"Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Adolescent ORION-16 or ORION-13 Studies","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":131,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03409744","title":"Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT07470723","title":"The ORIGIN-FH Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":false},{"nct_id":"NCT03156621","title":"Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":69,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT04034485","title":"Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"LIB Therapeutics LLC","has_results":false},{"nct_id":"NCT03399786","title":"Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT07037771","title":"A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Arrowhead Pharmaceuticals","has_results":false},{"nct_id":"NCT01588496","title":"Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03851705","title":"A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06723652","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Beijing Suncadia Pharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT06712771","title":"A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"Visirna Therapeutics HK Limited","has_results":false},{"nct_id":"NCT03403374","title":"Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT06009393","title":"Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Beijing Suncadia Pharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT07489209","title":"A Dose-exploration Study of EDP167 in HoFH","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Eddingpharm (Zhuhai) Co., Ltd.","has_results":false},{"nct_id":"NCT04233918","title":"Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT04031742","title":"A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Innovent Biologics (Suzhou) Co. Ltd.","has_results":false},{"nct_id":"NCT05611528","title":"Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Daniel Gaudet","has_results":false},{"nct_id":"NCT03933293","title":"A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT02265952","title":"Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT02963311","title":"A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"The Medicines Company","has_results":true},{"nct_id":"NCT02434497","title":"A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04080050","title":"A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501","phase":"","overall_status":"UNKNOWN","enrollment_count":8,"lead_sponsor_name":"REGENXBIO Inc.","has_results":false},{"nct_id":"NCT04148001","title":"Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Patients","phase":"","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"REGENXBIO Inc.","has_results":false},{"nct_id":"NCT03455777","title":"Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Akcea Therapeutics","has_results":false},{"nct_id":"NCT06500598","title":"Compassionate Use of Evinacumab","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false}],"total":29},"guidelines":[],"source":"Drug Landscape verified database"}